Shanghai Henlius Biotech, Inc.

Henlius (2696. HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global Innovation centers and a Shanghai-based manufacturing facility certificated by China and the EU Good Manufacturing Practice (GMP).

More about Henlius
  • Shanghai Henlius Biotech, Inc.

    Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HLX10 (anti-PD-1 mAb) as backbone. Up to date, the Company has successfully marketed 3 innovative monoclonal antibodies (mAbs), including 汉利康Ⓡ (rituximab), the first China-developed biosimilar, 汉曲优® (trastuzumab, Zercepac in the EU), the first China-developed mAb biosimilar approved both in China and in the EU, and 汉达远® (adalimumab), the first autoimmune disease treatment product developed by the Company. In addition, the NDA of HLX04 bevacizumab and HLX01 rituximab for new indications of rheumatoid arthritis is under review. Henlius has also concurrently carried out more than 20 clinical trials on 10 products and 8 combination regimens worldwide. The external authorization of the products fully covers the mainstream biopharmaceutical markets in Europe and the United States, as well as many emerging countries.